MR giants merge to form GfK-TNS

GfK and TNS are moving forward on a “merger of equals,” to be completed Q4, 2008, pending board approvals. The announcement was made June 3.

Hajo Riesenbeck, currently chairman of GfK's supervisor board, will become GfK-TNS chairman of the board.

Donald Brydon, currently TNS chairman of the board, will become the senior independent director. David Lowden, chief executive of TNS, will retain his title, as will Christian Weller von Ahlefeld, chief financial officer at GfK.

GfK-TNS will operate in 111 countries, with a global head office in London and a German head office in Nürnberg, according to the announcement.

Upon full acceptance of the deal, TNS shareholders and GfK shareholders will each hold approximately 50% of the share capital of GfK-TNS following completion of the merger.

The proposed merger was first announced in April.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.